 CAMBRIDGE, Mass., June 28, 2021 GLOBE NEWSWIRE -- Agios Pharmaceuticals, Inc. NASDAQ: AGIO, a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a Marketing Authorisation Application MAA for mitapivat to the European Medicines Agency EMA for the treatment of adults with pyruvate kinase PK deficiency in the European Union. This submission follows the companys recent New Drug Application NDA submission of mitapivat to the U.S. Food and Drug Administration FDA for treatment of adults with PK deficiency in the U.S. 